Case Report

Teriparatide Treatment for An Atypical Fracture of the Femoral Shaft : A Case Report

Yusuke Oshita*1), Takuma Kuroda1), Koji Ishikawa2), Takashi Nagai2), Keikichi Kawasaki1), Koji Kanaki3) and Katsunori Inagaki2)

Abstract: An 82-year-old woman had been taking alendronate for 5 years and 5 months, which had been prescribed for osteoporosis at a local clinic. Severe left thigh pain began without any trauma. X-ray, computed tomography and magnetic resonance imaging findings showed atypical femoral fracture (AFF). Treatment with teriparatide and weight-bearing therapy was selected. Bone union was achieved without surgery. Teriparatide has been reported to promote AFF healing. At four years and 9 months from the beginning of treatment, our patient has no left femoral pain and no impairment to activities of daily living. Careful follow-up will be necessary as long-term outcomes of conservative AFF treatment have not been reported to date.

Key words: atypical fracture, teriparatide, non-surgical procedure, alendronate, osteoporosis

Introduction

We report the case of a patient who sustained an atypical femoral fracture (AFF) during alendronate therapy for osteoporosis. Bone union was achieved with concurrent teriparatide administration and weight-bearing therapy.

Case report

We treated an 82-year-old woman whose chief complaint was left femoral pain. She had no recent history of trauma, but she had previously been diagnosed with osteoporosis and had been taking 35 mg of alendronate once weekly for 5 years and 5 months. On developing idiopathic left femoral pain, she was treated with non-steroidal anti-inflammatory drugs by a local physician. However, her symptoms were not alleviated. Therefore, she was referred to our hospital 3 months after she first experienced the pain. On initial examination, the patient had gait disturbance and experienced pain while turning over in bed. X-ray images showed a transverse...
fracture in the left femoral shaft that extended to about half the bone diameter (Fig. 1). Computed tomography confirmed cortical bone thickening and the fracture line. Fat-suppressed magnetic resonance imaging (MRI) showed high signal intensity (Fig. 2). No malignant lesions were observed. A plain radiograph of the right femur showed cortical thickness but no radiolucent line.

The patient’s blood bone biochemistry showed that she had abnormally low levels of metabolic markers for bone turnover, including P1NP (15.4 µg/l, range, 16.4–98.2 µg/l). Her
bone mineral density relative to the young adult mean was 58% for the distal one-third of the radius, 78% for the femoral neck, and 82% for the anterior–posterior density of the L2–L4 vertebrae. Based on clinical and imaging findings, we diagnosed bisphosphonate-induced atypical fracture. The patient was hospitalized for treatment because she lived alone and had difficulty with activities of daily living. Subsequently, teriparatide therapy (56.5 µg teriparatide acetate per week) was initiated and we established an exercise program of walking with partial (half) weight-bearing using double crutches. The patient was discharged 3 weeks after her gait stabilized. After 4 weeks of teriparatide therapy, the pain had been alleviated. An MRI scan showed a decrease in the luminosity change, standard x-ray images showed an increase in callus formation, and the patient could walk with full weight-bearing using crutches. Three months after treatment initiation, she could walk unassisted. At 4 months, her condition had further improved. In addition, the signal intensity changes that were previously evident on MRI scanning had mostly disappeared (Fig. 3). Four years and 9 months since her treatment began, she has no left femoral pain and no impairment to activities of daily living.

Discussion

During treatment of osteoporosis with bisphosphonate, bone metabolism is excessively suppressed, which can cause AFF. The incidence of AFF increases with the use of bisphosphonate for more than 5 years\(^1\), although a shorter duration of therapy may also lead to AFF\(^2, 3\). Interestingly, a diagnostic criteria task force of the American Society for Bone and Mineral Research has reported the involvement of femoral curvature\(^4-7\). Thus, the exact pathological process is unclear, and the treatment strategy for AFF is controversial. Also, cases of delayed union in patients treated with bisphosphonates have been reported\(^8-10\). However, by treating our patient with teriparatide, we achieved bone union much sooner than described in
other reported cases of healed fractures. In reports of conservative treatment, surgery was required more often for subtrochanteric fractures than for diaphyseal (shaft) fractures. The present patient sustained a femoral shaft fracture, which we were able to treat conservatively. A case of subtrochanteric AFF in which bone union was achieved following intramedullary nail fixation and administration of teriparatide therapy has also been reported. However, we were able to achieve bone union before complete bone fracture occurred. In cases of complete fracture, further treatment would be needed to prevent the onset of displacement. Generally, conservative treatment is only an option for cases of incomplete fracture, but AFF rarely heals spontaneously and most patients require surgery. Specifically, teriparatide appears to promote AFF healing, so weight-bearing gait rehabilitation during teriparatide treatment might be a good conservative treatment option for some patients. We believe that teriparatide therapy enhanced the bone union in our patient. We also believe that teriparatide treatment is likely to result in acceptable long-term outcomes, given the medium-term clinical success achieved with our patient.

**Conclusion**

We report our experience of treating a patient who developed an atypical fracture after 5 years and 5 months of alendronate therapy. The bone fracture site healed following teriparatide therapy. We conclude that conservative treatment might be a good treatment option in such cases.

**Conflicts of interest disclosure**

The authors have no conflicts of interest to disclose.

**Patient consent**

We obtained informed consent from our patient to publish her data.

**References**

6. Oh Y, Wakabayashi Y, Kurosa Y, et al. Stress fracture of the bowed femoral shaft is another cause of atypical


[Received August 27, 2018: Accepted November 1, 2018]